BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: van der Feen C, van der Doef HP, van der Ent CK, Houwen RH. Ursodeoxycholic acid treatment is associated with improvement of liver stiffness in cystic fibrosis patients. Journal of Cystic Fibrosis 2016;15:834-8. [DOI: 10.1016/j.jcf.2016.07.009] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Galante GJ. Defining and Treating Cystic Fibrosis Liver Disease: Some Things Old and Some Things New. J Cyst Fibros 2022;21:199-201. [PMID: 35337600 DOI: 10.1016/j.jcf.2022.03.004] [Reference Citation Analysis]
2 Cabrera D, Arab JP, Arrese M. UDCA, NorUDCA, and TUDCA in Liver Diseases: A Review of Their Mechanisms of Action and Clinical Applications. In: Fiorucci S, Distrutti E, editors. Bile Acids and Their Receptors. Cham: Springer International Publishing; 2019. pp. 237-64. [DOI: 10.1007/164_2019_241] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
3 Esteves CZ, de Aguiar Dias L, de Oliveira Lima E, de Oliveira DN, Rodrigues Melo CFO, Delafiori J, Souza Gomez CC, Ribeiro JD, Ribeiro AF, Levy CE, Catharino RR. Skin Biomarkers for Cystic Fibrosis: A Potential Non-Invasive Approach for Patient Screening. Front Pediatr 2017;5:290. [PMID: 29376041 DOI: 10.3389/fped.2017.00290] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
4 Staufer K. Current Treatment Options for Cystic Fibrosis-Related Liver Disease. Int J Mol Sci 2020;21:E8586. [PMID: 33202578 DOI: 10.3390/ijms21228586] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
5 Keely SJ, Steer CJ, Lajczak-McGinley NK. Ursodeoxycholic acid: a promising therapeutic target for inflammatory bowel diseases? Am J Physiol Gastrointest Liver Physiol 2019;317:G872-81. [PMID: 31509435 DOI: 10.1152/ajpgi.00163.2019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
6 Sakiani S, Kleiner DE, Heller T, Koh C. Hepatic Manifestations of Cystic Fibrosis. Clin Liver Dis 2019;23:263-77. [PMID: 30947876 DOI: 10.1016/j.cld.2018.12.008] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 4.7] [Reference Citation Analysis]
7 Evans WRH, Nicoli ER, Wang RY, Movsesyan N, Platt FM. Case Report: Ursodeoxycholic acid treatment in Niemann-Pick disease type C; clinical experience in four cases. Wellcome Open Res 2017;2:75. [PMID: 29119141 DOI: 10.12688/wellcomeopenres.11854.1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
8 Houwen RH, van der Woerd WL, Slae M, Wilschanski M. Effects of new and emerging therapies on gastrointestinal outcomes in cystic fibrosis. Current Opinion in Pulmonary Medicine 2017;23:551-5. [DOI: 10.1097/mcp.0000000000000423] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
9 Kamal N, Surana P, Koh C. Liver disease in patients with cystic fibrosis. Curr Opin Gastroenterol 2018;34:146-51. [PMID: 29438119 DOI: 10.1097/MOG.0000000000000432] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
10 Davison S. Assessment of liver disease in cystic fibrosis. Paediatr Respir Rev 2018;27:24-7. [PMID: 29933897 DOI: 10.1016/j.prrv.2018.05.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
11 Shah P, Lowery E, Chaparro C, Visner G, Hempstead SE, Abraham J, Bhakta Z, Carroll M, Christon L, Danziger-Isakov L, Diamond JM, Lease E, Leonard J, Litvin M, Poole R, Vlahos F, Werchan C, Murray MA, Tallarico E, Faro A, Pilewski JM, Hachem RR. Cystic fibrosis foundation consensus statements for the care of cystic fibrosis lung transplant recipients. J Heart Lung Transplant 2021;40:539-56. [PMID: 34103223 DOI: 10.1016/j.healun.2021.04.011] [Reference Citation Analysis]
12 Wiecek S, Fabrowicz P, Wos H, Kordys-darmolinska B, Cebula M, Gruszczynska K, Grzybowska-chlebowczyk U, Liu Z. Assessment of Liver Fibrosis with the Use of Elastography in Paediatric Patients with Diagnosed Cystic Fibrosis. Disease Markers 2022;2022:1-8. [DOI: 10.1155/2022/4798136] [Reference Citation Analysis]
13 Scott J, Jones AM, Piper Hanley K, Athwal VS. Review article: epidemiology, pathogenesis and management of liver disease in adults with cystic fibrosis. Aliment Pharmacol Ther 2022. [PMID: 35048397 DOI: 10.1111/apt.16749] [Reference Citation Analysis]
14 Enaud R, Frison E, Missonnier S, Fischer A, de Ledinghen V, Perez P, Bui S, Fayon M, Chateil JF, Lamireau T. Cystic fibrosis and noninvasive liver fibrosis assessment methods in children. Pediatr Res 2021. [PMID: 33731812 DOI: 10.1038/s41390-021-01427-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Colombo C, Alicandro G, Oliver M, Lewindon PJ, Ramm GA, Ooi CY, Alghisi F, Kashirskaya N, Kondratyeva E, Corti F, Padoan R, Asherova I, Evans H, de Monestrol I, Strandvik B, Lindblad A; CF UDCA study group. Ursodeoxycholic acid and liver disease associated with cystic fibrosis: A multicenter cohort study. J Cyst Fibros 2021:S1569-1993(21)00090-4. [PMID: 33814323 DOI: 10.1016/j.jcf.2021.03.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
16 Castellani C, Duff AJA, Bell SC, Heijerman HGM, Munck A, Ratjen F, Sermet-Gaudelus I, Southern KW, Barben J, Flume PA, Hodková P, Kashirskaya N, Kirszenbaum MN, Madge S, Oxley H, Plant B, Schwarzenberg SJ, Smyth AR, Taccetti G, Wagner TOF, Wolfe SP, Drevinek P. ECFS best practice guidelines: the 2018 revision. J Cyst Fibros 2018;17:153-78. [PMID: 29506920 DOI: 10.1016/j.jcf.2018.02.006] [Cited by in Crossref: 229] [Cited by in F6Publishing: 175] [Article Influence: 57.3] [Reference Citation Analysis]
17 Gominon AL, Frison E, Hiriart JB, Vergniol J, Clouzeau H, Enaud R, Bui S, Fayon M, de Ledinghen V, Lamireau T. Assessment of Liver Disease Progression in Cystic Fibrosis Using Transient Elastography. J Pediatr Gastroenterol Nutr 2018;66:455-60. [PMID: 29112089 DOI: 10.1097/MPG.0000000000001822] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
18 van de Peppel IP, Bertolini A, Jonker JW, Bodewes FAJA, Verkade HJ. Diagnosis, follow-up and treatment of cystic fibrosis-related liver disease. Curr Opin Pulm Med 2017;23:562-9. [PMID: 28837442 DOI: 10.1097/MCP.0000000000000428] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]